Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cytokinetics (CYTK)

Cytokinetics Q2 revenue falls to $28.6 million; net loss widens to $198.8 million

Negative Impact 4 of 5 earnings Written later

Cytokinetics reported second quarter 2026 total revenue of $28.6 million, down from $66.8 million a year earlier, when the company recorded $64.4 million in license and milestone revenue. The net loss widened to $198.8 million, or $(1.50) per share, from $134.4 million, or $(1.12) per share. The company also raised its full year 2026 GAAP combined R&D and SG&A expense guidance, which it attributed to commercial readiness investments ahead of a potential 2027 nHCM launch of MYQORZO.

Key points

  • Total revenue was $28.6 million in Q2 2026 versus $66.8 million in Q2 2025; Q2 2026 had no license and milestone revenue.
  • MYQORZO net product revenue was $25.3 million, including $23.0 million from the U.S. and $2.3 million from Europe.
  • Net loss was $198.8 million, or $(1.50) per share, compared with $134.4 million, or $(1.12) per share, a year earlier.
  • 2026 GAAP combined R&D and SG&A expense guidance rose to $860 million to $890 million from $830 million to $870 million.

The filing

CompanyCytokinetics (CYTK)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:11 PM ET
Accession number0001193125-26-338021

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.